Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

Rhea-AI Summary

Eiger BioPharmaceuticals, based in Palo Alto, California, announced participation in two investor conferences on August 10, 2021. David Cory, President and CEO, will engage in a fireside chat at the BTIG Virtual Healthcare Conference at 1:00 PM ET, followed by a panel discussion on liver diseases at the Wedbush PacGrow Healthcare Virtual Conference at 2:20 PM ET. Eiger's lead programs target hepatitis delta virus with treatments in Phase 3 trials. The company's first FDA-approved product is Zokinvy, designed for treating Hutchinson-Gilford Progeria Syndrome.

PALO ALTO, Calif., Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate in two investor conference events in August:

• BTIG Virtual Healthcare Conference 2021
• Fireside chat
• Tuesday, August 10 at 1:00 PM ET 
• 2021 Wedbush PacGrow Healthcare Virtual Conference
• "Live-r Let Die – Updates in Liver Disease" panel discussion
• Tuesday, August 10 at 2:20 PM ET

Eiger will also host one-on-meetings with investors at both conferences. 

A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.  A replay of the webcast will be available approximately one hour following the live event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon Lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3.

Zokinvy^® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:

Charles Butler – VP, Investor Relations and Corporate Communications
Email: cbutler@eigerbio.com
Phone: 1-650-272-6138

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences-301347526.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is the schedule for EIGR's participation in August 2021 investor conferences?

Eiger BioPharmaceuticals will participate in two investor conferences on August 10, 2021. The BTIG Virtual Healthcare Conference features a fireside chat at 1:00 PM ET, followed by the Wedbush PacGrow Healthcare Virtual Conference's panel discussion on liver diseases at 2:20 PM ET.

How can I watch the EIGR panel discussion during the Wedbush conference?

A live webcast of Eiger's panel discussion at the Wedbush PacGrow Healthcare Virtual Conference will be available on Eiger's website in the Investors section, with a replay accessible about one hour after the live event.

What are Eiger's key clinical programs for rare diseases?

Eiger BioPharmaceuticals focuses on developing therapies for serious rare diseases, including treatments for hepatitis delta virus infection and its first FDA-approved product, Zokinvy, for Hutchinson-Gilford Progeria Syndrome.

What is the significance of EIGR's participation in investor conferences?

Eiger's participation allows the company to showcase its innovations in rare disease therapies and engage with investors about its clinical programs and future developments.